HIV drug resistance tests are here to stay

被引：6

作者：

Boucher, CAB ^{[1
]}

机构：

[1] Univ Utrecht Hosp, Dept Clin Virol, Utrecht, Netherlands

来源：

CURRENT OPINION IN INFECTIOUS DISEASES | 1999年 / 12卷 / 01期

关键词：

D O I：

10.1097/00001432-199902000-00005

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The clinical indications for HIV drug resistance testing are discussed, The major limitations of using resistance testing in the clinical setting are the lack of evidence for a clinical benefit, the costs and the amount of knowledge required for a good interpretation of the results. in those situations in which these limitations can be overcome or are considered less important, resistance testing may be used today, For widespread clinical use, however, trials creating large databases and the design of expert systems translating the results for the use in individual patients will be required, Curr Opin Infect Dis 12:27-32. (C) 1999 Lippincott Williams & Wilkins.

引用

页码：27 / 32

页数：6

共 15 条

[1]

BROWN AJL, 1998, 241 ACTG

[2] HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial [J].

BrunVezinet, F ;

Boucher, C ;

Loveday, C ;

Descamps, D ;

Fauveau, V ;

Izopet, J ;

Jeffries, D ;

Kaye, S ;

Krzyanowski, C ;

Nunn, A ;

Schuurman, R ;

Seigneurin, JM ;

Tamalet, C ;

Tedder, R ;

Weber, J ;

Weverling, GJ ;

Aber, V ;

Aboulker, JP ;

Babiker, AG ;

Bragman, K ;

Breckenridge, AM ;

Carbon, C ;

Charreau, I ;

Chene, G ;

Collis, P ;

Cooper, D ;

Darbyshire, JH ;

Dormont, J ;

Fiddian, P ;

Flepp, M ;

Gazzard, B ;

Goebel, FD ;

Hooker, M ;

Lange, J ;

Luthy, R ;

Peto, TEA ;

Reiss, P ;

Seligmann, M ;

Stone, AB ;

Thomis, J ;

Vella, S ;

Walckenaer, G ;

Warrell, D ;

Weller, IVD ;

Wilber, R ;

Yeni, P ;

Yeo, J ;

Withnall, R ;

Babiker, A ;

Bloch, J .

LANCET, 1997, 350 (9083) :983-990

[3]

Centers For Disease Control (Usa), 1998, Morbidity and Mortality Weekly Report, V47, P1

[4]

DEEKS SG, 1998, CORRELATION BASELINE

[5]

Durant J, 1998, AIDS, V12, pS16

[6]

HARRIGAN PR, 1998, BASELINE RESISTANCE

[7] Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors [J].

Hecht, FM ;

Grant, RM ;

Petropoulos, CJ ;

Dillon, B ;

Chesney, MA ;

Tian, H ;

Hellmann, NS ;

Bandrapalli, NI ;

Digilio, L ;

Branson, B ;

Kahn, JO .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (05) :307-311

[8] Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type β-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp. -: J Antimicrob Chemother 1998; 42:269-270 [J].

Vahaboglu, H ;

Saribas, S ;

Akbal, H ;

Ozturk, R ;

Yucel, A .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (02) :269-270

[9] Antiretroviral drug resistance testing in adults with HIV infection -: Implications for clinical management [J].

Hirsch, MS ;

Conway, B ;

D'Aquila, RT ;

Johnson, VA ;

Brun-Vézinet, F ;

Clotet, B ;

Demeter, LM ;

Hammer, SM ;

Jacobsen, DM ;

Kuritzkes, DR ;

Loveday, C ;

Mellors, JW ;

Vella, S ;

Richman, DD .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (24) :1984-1991

[10]

LANIER R, 1998, GENOTYPIC PHENOTYPIC

← 1 2 →